0K9.F - FSD Pharma Inc.

Frankfurt - Frankfurt Delayed Price. Currency in EUR
0.2010
+0.0010 (+0.50%)
As of 8:15AM CET. Market open.
Stock chart is not supported by your current browser
Previous Close0.2000
Open0.2120
Bid0.198 x 0
Ask0.209 x 0
Day's Range0.2010 - 0.2120
52 Week Range0.0780 - 0.6380
Volume1,000
Avg. Volume401,504
Market Cap268.11M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.001
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • FSD Pharma Announces Collaboration and License Agreement with World Class Extractions
    CNW Group5 days ago

    FSD Pharma Announces Collaboration and License Agreement with World Class Extractions

    TORONTO , Dec. 6, 2018 /CNW/ - FSD Pharma Inc. ("FSD Pharma") (HUGE.CN) (FSDDF) (0K9.F), which, through its wholly-owned subsidiary, FV Pharma Inc. ("FV Pharma"), is a licensed producer pursuant to the Cannabis Act, announced today that it has entered into a definitive Collaboration and License Agreement (the "Agreement") with World Class Extractions Inc. ("World Class"), a company that has developed a unique extraction process designed to produce quality, potent cannabis extracts. World Class is also in the process of completing its own previously announced reverse takeover of CBD Med Research Corp. (the "RTO"), and submitted its initial listing application to the Canadian Securities Exchange (the "CSE") late last week. Under the terms of the agreement and a related lease, FSD Pharma will provide World Class with space at its 620,000 square foot facility in Cobourg, Ontario (the "FSD Facility"), assist it in obtaining an extraction license from Health Canada, and provide World Class with the raw cannabis needed to produce cannabis extracts.

  • Business Wire5 days ago

    FSD Pharma Announces Collaboration and License Agreement with World Class Extractions

    FSD Pharma Inc. (“FSD Pharma”) (HUGE.CN) (FSDDF) (0K9.F), which, through its wholly-owned subsidiary, FV Pharma Inc. (“FV Pharma”), is a licensed producer pursuant to the Cannabis Act, announced today that it has entered into a definitive Collaboration and License Agreement (the “Agreement”) with World Class Extractions Inc. (“World Class”), a company that has developed a unique extraction process designed to produce quality, potent cannabis extracts. World Class is also in the process of completing its own previously announced reverse takeover of CBD Med Research Corp. (the “RTO”), and submitted its initial listing application to the Canadian Securities Exchange (the “CSE”) late last week.

  • Business Wire6 days ago

    FSD Pharma Congratulates Partner Canntab on Launch of Research Partnership with Leading Orthopaedic Surgeon Dr. Don Garbuz, M.D.

    FSD Pharma Inc. (“FSD Pharma”) (HUGE.CN) (FSDDF) (0K9.F) today congratulated strategic partner Canntab Therapeutics Limited (“Canntab”) (CSE:PILL) (TBF1.F) on the launch of a research partnership with leading orthopaedic surgeon Dr. Don Garbuz, M.D. Dr. Garbuz will be the lead investigator on a clinical research study at the University of British Columbia subject to the University’s approval that aims to show the potential for reduction or elimination of the use of opiates in orthopaedic patients using Canntab’s sustained release tablets. Canntab will create the tablets for the study in Cobourg, Ontario with FSD Pharma in furtherance of their collaboration and license agreement dated September 17, 2018.

  • FSD Pharma congratulates partner Canntab on launch of research partnership with leading orthopaedic surgeon Dr. Don Garbuz, M.D.
    CNW Group6 days ago

    FSD Pharma congratulates partner Canntab on launch of research partnership with leading orthopaedic surgeon Dr. Don Garbuz, M.D.

    FSD Pharma congratulates partner Canntab on launch of research partnership with leading orthopaedic surgeon Dr. Don Garbuz, M.D.

  • Business Wire8 days ago

    FSD Pharma Achieves Over 4 Billion Shares Traded in First 6 Months

    FSD Pharma Inc. (“FSD” or the “Company”) (HUGE.CN) (FSDDF) (0K9.F) announced today that the Company has traded over four Billion Class B subordinate voting shares in its first six months of trading on the Canadian Securities Exchange (“CSE”). During the period of May 29, 2018 to November 29, 2018, the Company traded exactly 4,041,346,300 Class B subordinate voting shares on the CSE. The Company wishes to again thank all its shareholders and stakeholders for their support to date, which has resulted in another record-breaking launch into the Canadian cannabis marketplace.

  • FSD Pharma Achieves Over 4 Billion Shares Traded in First 6 Months
    CNW Group8 days ago

    FSD Pharma Achieves Over 4 Billion Shares Traded in First 6 Months

    TORONTO , Dec. 3, 2018 /CNW/ - FSD Pharma Inc. ("FSD" or the "Company") (HUGE.CN) (FSDDF) (0K9.F) announced today that the Company has traded over four Billion Class B subordinate voting shares in its first six months of trading on the Canadian Securities Exchange ("CSE"). During the period of May 29, 2018 to November 29, 2018 , the Company traded exactly 4,041,346,300 Class B subordinate voting shares on the CSE. The Company wishes to again thank all its shareholders and stakeholders for their support to date, which has resulted in another record-breaking launch into the Canadian cannabis marketplace.

  • FSD Pharma Reports Positive Q3 Results
    CNW Group11 days ago

    FSD Pharma Reports Positive Q3 Results

    TORONTO , Nov. 30, 2018 /CNW/ - FSD Pharma Inc. ("FSD Pharma" or the "Company") (HUGE.CN) (FSDDF) (0K9.F) today reported its financial and operational results for the third quarter of fiscal 2018, ended September 30, 2018 .

  • Business Wire11 days ago

    FSD Pharma Reports Positive Q3 Results

    FSD Pharma Inc. today reported its financial and operational results for the third quarter of fiscal 2018, ended September 30, 2018.

  • Business Wire12 days ago

    FSD Pharma and SciCann Therapeutics to Present at the iCDP Summit in Boston

    FSD Pharma Inc. (“FSD Pharma”) (HUGE.CN) (FSDDF) (0K9.F) announced today that Dr. Zohar Koren, CEO of its Strategic Partner SciCann Therapeutics (“SciCann”) and Head of its Scientific Advisory Board, will present at the International Cannabinoid-Derived Pharmaceuticals Summit (“iCDP Summit”) in Boston, on December 11-12, 2018. The iCDP Summit is a central meeting place for leading pharma companies, research experts and clinical pioneers in the field of Cannabinoid Derived Pharmaceutical development, including delegates of field leaders such as GW Pharmaceuticals plc, Tilray Inc. and GB Sciences Inc. The Summit speakers and participants will discuss issues such as complex Cannabinoid pharmacology, formulations and delivery systems, clinical studies, patient education and commercial challenges.

  • FSD Pharma Facility Valued at $105,000,000 with 3,000,000 ft Expansion Assessed at $420,000,000
    CNW Group13 days ago

    FSD Pharma Facility Valued at $105,000,000 with 3,000,000 ft Expansion Assessed at $420,000,000

    TORONTO , Nov. 28, 2018 /CNW/ - FSD Pharma Inc. ("FSD Pharma" or the "Company") (HUGE.CN) (FSDDF) (0K9.F) announced today that the Company's facility and land located at 520 William Street in Cobourg, Ontario has a Fair Market Value of $105,000,000 according to a recent Comprehensive Property Value Assessment by a commercial real estate assessment specialist issued on November 20, 2018 . Due to the nature of the property, the current value assessment was conducted using the Cost Approach and incorporated property improvements of over $10,000,000 by the Company since acquisition, ongoing Joint Venture Capital Improvements by Auxly Cannabis Group Inc. (TSX.V – XLY) of over $50,000,000 and Government-Issued Licenses for the production and sale of cannabis attached to the footprint of the property.

  • Business Wire13 days ago

    FSD Pharma Facility Valued at $105,000,000 With 3,000,000 ft Expansion Assessed at $420,000,000

    FSD Pharma Inc. (“FSD Pharma” or the “Company”) (HUGE.CN) (FSDDF) (0K9.F) announced today that the Company’s facility and land located at 520 William Street in Cobourg, Ontario has a Fair Market Value of $105,000,000 according to a recent Comprehensive Property Value Assessment by a commercial real estate assessment specialist issued on November 20, 2018. Due to the nature of the property, the current value assessment was conducted using the Cost Approach and incorporated property improvements of over $10,000,000 by the Company since acquisition, ongoing Joint Venture Capital Improvements by Auxly Cannabis Group Inc. (TSX.V – XLY) of over $50,000,000 and Government-Issued Licenses for the production and sale of cannabis attached to the footprint of the property.

  • GlobeNewswire14 days ago

    FSD Pharma’s New CEO is a Top GW Pharma Executive -- CFN Media

    SEATTLE, Nov. 27, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing FSD Pharma Inc. (CSE:HUGE) (FSDDF) (0K9.F). The company recently appointed Rupert Haynes as Chief Executive Officer, which is significant because he formerly held a leadership position at GW Pharmaceuticals plc—the world leader in cannabinoid research and development. Investors may want to take a closer look at the company given these developments and the ongoing progress at its Cobourg facility in Ontario.

  • FSD Pharma Appoints Top GW Pharmaceuticals Executive, Rupert Haynes, as Chief Executive Officer
    CNW Group15 days ago

    FSD Pharma Appoints Top GW Pharmaceuticals Executive, Rupert Haynes, as Chief Executive Officer

    Mr. Haynes is a highly accomplished healthcare executive with nearly three decades of global pharmaceutical experience having most recently held the position of Head of Global Marketing at GW Pharmaceuticals (GWPH) in the United Kingdom . In his new role with FSD Pharma, Mr. Haynes will continue to work out of the United Kingdom , which will support FSD Pharma's strategy of expanding its global footprint.

  • Business Wire15 days ago

    FSD PHARMA Appoints Top GW Pharmaceuticals Executive, Rupert Haynes, as Chief Executive Officer

    Mr. Haynes is a highly accomplished healthcare executive with nearly three decades of global pharmaceutical experience having most recently held the position of Head of Global Marketing at GW Pharmaceuticals (GWPH) in the United Kingdom. In his new role with FSD Pharma, Mr. Haynes will continue to work out of the United Kingdom, which will support FSD Pharma’s strategy of expanding its global footprint.

  • Business Wire27 days ago

    FSD Pharma Adds David Urban to Board of Directors

    Mr. Urban is an accomplished business and government relations executive. In the field of politics, Mr. Urban has achieved success serving as an advisor to campaigns at the highest levels, including the President of the United States, the United States Senate and United States House of Representatives.

  • FSD Pharma adds David Urban to Board of Directors
    CNW Group27 days ago

    FSD Pharma adds David Urban to Board of Directors

    Mr. Urban is an accomplished business and government relations executive. In the field of politics, Mr. Urban has achieved success serving as an advisor to campaigns at the highest levels, including the President of the United States , the United States Senate and United States House of Representatives.

  • Business Wire28 days ago

    FSD Pharma Receives License to Sell to Other Licensed Producers and Expands Growth Production Footprint

    FSD Pharma Inc. (“FSD Pharma” or the “Company”) (HUGE.CN) (FSDDF) (0K9.F) announced today that the license of its wholly-owned subsidiary, FV Pharma Inc. (“FV Pharma”) under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”) has been migrated to the Cannabis Act and its regulations, effective November 8, 2018. The issuance of the new cannabis license includes the ability to sell cannabis to other licensed producers in accordance with subsection 11(5) of the Cannabis Regulations. As of November 7, 2018, FV Pharma also received license amendments approving all of the remaining 25,000 square feet currently built out for additional grow and operations.

  • FSD Pharma Receives License to Sell to Other Licensed Producers and Expands Growth Production Footprint
    CNW Group28 days ago

    FSD Pharma Receives License to Sell to Other Licensed Producers and Expands Growth Production Footprint

    TORONTO , Nov. 13, 2018 /CNW/ - FSD Pharma Inc. ("FSD Pharma" or the "Company") (HUGE.CN) (FSDDF) (0K9.F) announced today that the license of its wholly-owned subsidiary, FV Pharma Inc. ("FV Pharma") under the Access to Cannabis for Medical Purposes Regulations ("ACMPR") has been migrated to the Cannabis Act and its regulations, effective November 8, 2018 . As of November 7, 2018 , FV Pharma also received license amendments approving all of the remaining 25,000 square feet currently built out for additional grow and operations. The Company continues to move aggressively to achieve its next significant development of a further production footprint of 220,000 square feet.

  • GlobeNewswirelast month

    SciCann Therapeutics Announces Positive ISA Report for “Steady Stomach” CBD Combination Therapy Patent

    SciCann Therapeutics Inc. (“SciCann”) announced today it has received a positive International Search Authority (ISA) report from the Patent Cooperation Treaty (PCT) for its SCN-001 cannabidiol (CBD) combination therapy patent, the basis of its “Steady Stomach” product. The comprehensive prior art search performed by ISA for the PCT/IL2018/051000 patent application by SciCann led the agency to conclude that the enhanced CBD combination therapy claimed by the patent application is novel and inventive. SciCann’s strategic partner for the development and commercialization of the “Steady Stomach” product is FSD Pharma Inc. (“FSD Pharma”) (CSE:HUGE) (FSDDF) (0K9.F), which under the terms of the agreement between the companies holds exclusive manufacturing and distribution rights for the product in Canada.

  • Business Wirelast month

    FSD Pharma Announces Positive ISA Report for “Steady Stomach” CBD Combination

    FSD Pharma Inc. (“FSD Pharma”) (HUGE.CN) (FSDDF) (0K9.F) announced today that its strategic R&D partner, SciCann Therapeutics Inc. (“SciCann”) received a positive International Search Authority (ISA) report from the Patent Cooperation Treaty (PCT) for its SCN-001 cannabidiol (CBD) combination therapy, the basis of its “Steady Stomach” product. The comprehensive prior art search performed by ISA for the PCT/IL2018/051000 patent application by SciCann led the agency to conclude that the enhanced CBD combination therapy claimed by the patent application is novel and inventive.

  • FSD Pharma Announces Positive ISA Report for "Steady Stomach" CBD Combination
    CNW Grouplast month

    FSD Pharma Announces Positive ISA Report for "Steady Stomach" CBD Combination

    TORONTO , Nov. 6, 2018 /CNW/ - FSD Pharma Inc. ("FSD Pharma") (HUGE.CN) (FSDDF) (0K9.F) announced today that its strategic R&D partner, SciCann Therapeutics Inc. ("SciCann") received a positive International Search Authority (ISA) report from the Patent Cooperation Treaty (PCT) for its SCN-001 cannabidiol (CBD) combination therapy, the basis of its "Steady Stomach" product. The comprehensive prior art search performed by ISA for the PCT/IL2018/051000 patent application by SciCann led the agency to conclude that the enhanced CBD combination therapy claimed by the patent application is novel and inventive.

  • Business Wirelast month

    FSD Pharma Announces Launch of IBS Clinical Study

    FSD Pharma Inc. (“FSD Pharma” or “FSD”) (HUGE.CN) (FSDDF) (0K9.F) today announced the launch of a pilot clinical study in Pittsburgh, Pennsylvania, by its strategic R&D partner, SciCann Therapeutics (“SciCann”). The study is designed to test the safety and efficacy of SciCann’s proprietary “Steady Stomach” cannabidiol (CBD) combination product for the treatment of irritable bowel syndrome (IBS) patients. This study follows the previously reported efficacy results from a preclinical study in rodent models which demonstrated a three-fold increased efficacy in lowering abdominal inflammation levels with the advanced combination product as compared to CBD alone.

  • GlobeNewswirelast month

    Bloomberg Interviews FSD Pharma for Cannabis Shortage Feature -- CFN Media

    SEATTLE, Oct. 30, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing FSD Pharma Inc. (CSE:HUGE) (FSDDF) (0K9.F) and the cannabis shortage following legalization. Bloomberg recently interviewed the company to address the cannabis shortage issue. Canada may have legalized adult-use cannabis on October 17, but that doesn’t mean consumers are able to purchase the drug. According to Bloomberg, there are widespread shortages across the country, despite an ample supply of licensed producers awaiting approval from Health Canada.

  • FSD Pharma Announces Appointments of Dr. Raza Bokhari as Interim CEO and Co-Chairman, Anthony Durkacz as Co-Chairman and Zeeshan Saeed as President
    CNW Grouplast month

    FSD Pharma Announces Appointments of Dr. Raza Bokhari as Interim CEO and Co-Chairman, Anthony Durkacz as Co-Chairman and Zeeshan Saeed as President

    TORONTO , Oct. 29, 2018 /CNW/ - The Board of Directors of FSD Pharma Inc. ("FSD Pharma" or the "Company") (HUGE.CN) (FSDDF) (0K9.F) is pleased to announce the appointment of Dr. Raza Bokhari as interim CEO and Co-Chairman of the Board of Directors, replacing Thomas Fairfull. Dr. Bokhari brings a wealth of knowledge in global business and healthcare services. Physician turned entrepreneur, Dr. Bokhari has over the past several years developed outstanding expertise in aggregating and accelerating life sciences and healthcare services companies.

  • Business Wirelast month

    FSD Pharma Announces Appointments of Dr. Raza Bokhari as Interim CEO and Co-Chairman, Anthony Durkacz as Co-Chairman and Zeeshan Saeed as President

    The Board of Directors of FSD Pharma Inc. (“FSD Pharma” or the “Company”) (HUGE.CN) (FSDDF) (0K9.F) is pleased to announce the appointment of Dr. Raza Bokhari as interim CEO and Co-Chairman of the Board of Directors, replacing Thomas Fairfull. Dr. Bokhari brings a wealth of knowledge in global business and healthcare services. Physician turned entrepreneur, Dr. Bokhari has over the past several years developed outstanding expertise in aggregating and accelerating life sciences and healthcare services companies.